Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00371189 · ClinicalTrials.gov registry record · Phase 1
Adenovirus Vaccine for Malaria
A Phase 1 study of Plasmodium Falciparum Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 2
- Study locations
NCT00371189 is a Phase 1 study of Plasmodium Falciparum Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 75 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00371189, a Phase 1 study of Plasmodium Falciparum Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
Malaria is caused by a parasite carried by a mosquito. Currently, there is no vaccine licensed to prevent malaria. The purpose of this study is to find the most effective and safest dose of an experimental vaccine for the treatment of malaria. Participants will include 72 healthy adults, ages18 to 45, enrolled at Vanderbilt University Medical Center and Stanford University. Volunteers will receive 3 doses of either the malaria vaccine or placebo (contains no vaccine) by injection into a muscle at 0, 1 and 6 months. Investigators will evaluate how the body responds to increasing dosage strengths of the vaccine. Study procedures include physical exam, multiple blood draws, and completion of a memory aid (diary). Each participant will be actively involved in the study for about 12 months. Then, an annual phone call will be made to check for any serious illness events for a period of 5 years.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Ad35.CS.01 Circumsporozoite Malaria Vaccine
Study Locations (2)
California
- Stanford University School of Medicine - Stanford
Tennessee
- Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2007-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00371189
The ClinicalTrials.gov registry entry for NCT00371189 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plasmodium Falciparum Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00371189 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00371189 about?
NCT00371189 is a clinical study titled "Adenovirus Vaccine for Malaria". Malaria is caused by a parasite carried by a mosquito. Currently, there is no vaccine licensed to prevent malaria. The purpose of this study is to find the most effective and safest dose of an experimental vaccine for the treatment of malaria. Participants will include 72 healthy adults, ages18 to 4...
What is the current status of trial NCT00371189?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2007-01. Estimated completion is 2014-06.
What conditions does trial NCT00371189 study?
This clinical trial studies the following conditions: Plasmodium Falciparum Infection.
What interventions are being tested in trial NCT00371189?
The interventions under investigation include: Placebo (DRUG), Ad35.CS.01 Circumsporozoite Malaria Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00371189?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00371189 being conducted?
This trial has 2 study locations across California, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.